Search

Displaying results 5021 - 5030 of 10000 in total
  1. Drug

    Sus scrofa placenta

    go.drugbank.com/drugs/DB14243
    Investigational

    Sus scrofa placenta is an animal extract used in some OTC (over-the-counter) products. It is not an approved drug.

  2. Drug

    Pearl (hyriopsis cumingii)

    go.drugbank.com/drugs/DB14249
    Investigational

    Pearl (hyriopsis cumingii) is an animal extract used in some OTC (over-the-counter) products. It is not an approved drug.

  3. Drug

    Ostrea edulis shell

    go.drugbank.com/drugs/DB14251
    Investigational

    Ostrea edulis shell is an animal extract used in some OTC (over-the-counter) products. It is not an approved drug.

  4. Drug

    GSK-239512

    go.drugbank.com/drugs/DB15120
    Investigational

    GSK-239512 is under investigation in clinical trial NCT00474513 (An Imaging Study to Investigate the Distribution of GSK239512 in the Brain.).

  5. Drug

    Fosmanogepix

    go.drugbank.com/drugs/DB15183
    Investigational

    Fosmanogepix is under investigation in clinical trial NCT03604705 (An Efficacy and Safety Study of APX001 in Non-Neutropenic Patients With Candidemia).

  6. Drug

    Temelimab

    go.drugbank.com/drugs/DB15634
    Investigational

    Temelimab is under investigation in clinical trial NCT02782858 (Clinical Trial Assessing the HERV-W Env Antagonist Gnbac1 for Efficacy in MS).

  7. Drug

    Ciglitazone

    go.drugbank.com/drugs/DB09201
    Experimental

    Ciglitazone is a potent and selective PPARγ ligand with an EC50 of 3.0 µM. It is also an anti-hyperglycemic agent in the ob/ob murine model in vivo. … Ciglitazone significantly decreases VEGF production by human granulosa cells in an in vitro study, and may potentially be used in ovarian hyperstimulation syndrome.

  8. Drug

    G4544

    go.drugbank.com/drugs/DB05244
    Experimental

    G4544 is an oral gallium compound that enables oral absorption of the active ingredient contained in Ganite™ (gallium nitrate injection).

  9. Drug

    Recombinant SARS-CoV-2 Vaccine (Sf9 Cell)

    go.drugbank.com/drugs/DB16443
    Investigational

    It also provided protection in non-human primates to an in vivo challenge with SARS-CoV-2[A226853]. … In pre-clinical trial testing on mice, rabbits, and non-human primates, the candidate was able to induce a functional antibody response within 7-14 days of initial injection[A226853].

  10. Drug

    R1626

    go.drugbank.com/drugs/DB05060
    Experimental

    It achieves significant reductions in viral load in chronic hepatitis C patients infected with the difficult to treat genotype 1 virus. R1626 is very effective in inhibiting viral replication